Effect of PALB2 status on breast cancer precision medicine

Affiliations

¹ Department of Breast Oncology, Gustave Roussy Institute, Villejuif, France; INSERM UMR 981, Gustave Roussy Institute, Villejuif, France. Electronic address: suzette.delaloge@gustaveroussy.fr.
² Department of Genetics, Gustave Roussy Institute, Villejuif, France.
³ INSERM UMR 981, Gustave Roussy Institute, Villejuif, France; Laboratory of Genetic Stability and Tumorigenesis UMR 8200; Gustave Roussy Institute, Villejuif, France.

Comment

Suzette Delaloge et al. Lancet Oncol. 2015 Jun.

. 2015 Jun;16(6):598-600.

doi: 10.1016/S1470-2045(15)70182-8. Epub 2015 May 7.

¹ Department of Breast Oncology, Gustave Roussy Institute, Villejuif, France; INSERM UMR 981, Gustave Roussy Institute, Villejuif, France. Electronic address: suzette.delaloge@gustaveroussy.fr.
² Department of Genetics, Gustave Roussy Institute, Villejuif, France.
³ INSERM UMR 981, Gustave Roussy Institute, Villejuif, France; Laboratory of Genetic Stability and Tumorigenesis UMR 8200; Gustave Roussy Institute, Villejuif, France.

No abstract available

Comment on

Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis.
Cybulski C, Kluźniak W, Huzarski T, Wokołorczyk D, Kashyap A, Jakubowska A, Szwiec M, Byrski T, Dębniak T, Górski B, Sopik V, Akbari MR, Sun P, Gronwald J, Narod SA, Lubiński J; Polish Hereditary Breast Cancer Consortium. Cybulski C, et al. Lancet Oncol. 2015 Jun;16(6):638-44. doi: 10.1016/S1470-2045(15)70142-7. Epub 2015 May 7. Lancet Oncol. 2015. PMID: 25959805